333 related articles for article (PubMed ID: 21895627)
1. Parallel use of by-passing agents in haemophilia with inhibitors: a critical review.
Ingerslev J; Sørensen B
Br J Haematol; 2011 Oct; 155(2):256-62. PubMed ID: 21895627
[TBL] [Abstract][Full Text] [Related]
2. Safety of recombinant activated factor VII (rFVIIa) in patients with congenital haemophilia with inhibitors: overall rFVIIa exposure and intervals following high (>240 μg kg⁻¹) rFVIIa doses across clinical trials and registries.
Shapiro AD; Neufeld EJ; Blanchette V; Salaj P; Gut RZ; Cooper DL
Haemophilia; 2014 Jan; 20(1):e23-31. PubMed ID: 24354484
[TBL] [Abstract][Full Text] [Related]
3. Recombinant factor VIIa concentrate versus plasma-derived concentrates for treating acute bleeding episodes in people with haemophilia and inhibitors.
Matino D; Makris M; Dwan K; D'Amico R; Iorio A
Cochrane Database Syst Rev; 2015 Dec; 2015(12):CD004449. PubMed ID: 26677005
[TBL] [Abstract][Full Text] [Related]
4. Diagnosis and treatment of factor VIII and IX inhibitors in congenital haemophilia: (4th edition). UK Haemophilia Centre Doctors Organization.
Collins PW; Chalmers E; Hart DP; Liesner R; Rangarajan S; Talks K; Williams M; Hay CR;
Br J Haematol; 2013 Jan; 160(2):153-70. PubMed ID: 23157203
[No Abstract] [Full Text] [Related]
5. Ten-year experience of recombinant activated factor VII use in surgical patients with congenital haemophilia with inhibitors or acquired haemophilia in Japan.
Takedani H; Shima M; Horikoshi Y; Koyama T; Fukutake K; Kuwahara M; Ishiguro N
Haemophilia; 2015 May; 21(3):374-379. PubMed ID: 25521821
[TBL] [Abstract][Full Text] [Related]
6. Use of Bypassing Agents and Risk of Thromboembolic Events in Patients with Haemophilia and Inhibitors.
Bykov K; Bohn RL; Ewenstein BM; Seeger JD; Avorn J; Bateman BT
Thromb Haemost; 2017 Dec; 117(12):2267-2273. PubMed ID: 29212114
[TBL] [Abstract][Full Text] [Related]
7. Acquired haemophilia: management of bleeds and immune therapy to eradicate autoantibodies.
Holme PA; Brosstad F; Tjønnfjord GE
Haemophilia; 2005 Sep; 11(5):510-5. PubMed ID: 16128896
[TBL] [Abstract][Full Text] [Related]
8. Prophylaxis in 10 patients with severe haemophilia A and inhibitor: different approaches for different clinical situations.
Jiménez-Yuste V; Alvarez MT; Martín-Salces M; Quintana M; Rodriguez-Merchan C; Lopez-Cabarcos C; Velasco F; Hernández-Navarro F
Haemophilia; 2009 Jan; 15(1):203-9. PubMed ID: 19149850
[TBL] [Abstract][Full Text] [Related]
9. Safety update on the use of recombinant factor VIIa and the treatment of congenital and acquired deficiency of factor VIII or IX with inhibitors.
Abshire T; Kenet G
Haemophilia; 2008 Sep; 14(5):898-902. PubMed ID: 18684126
[TBL] [Abstract][Full Text] [Related]
10. Recombinant factor VIIa (eptacog alfa): a pharmacoeconomic review of its use in haemophilia in patients with inhibitors to clotting factors VIII or IX.
Lyseng-Williamson KA; Plosker GL
Pharmacoeconomics; 2007; 25(12):1007-29. PubMed ID: 18047387
[TBL] [Abstract][Full Text] [Related]
11. Elective orthopaedic surgery for haemophilia patients with inhibitors: single centre experience of 40 procedures and review of the literature.
Caviglia H; Candela M; Galatro G; Neme D; Moretti N; Bianco RP
Haemophilia; 2011 Nov; 17(6):910-9. PubMed ID: 21342367
[TBL] [Abstract][Full Text] [Related]
12. Use of recombinant factor VIIa (NovoSeven) in a haemophilia A patient with inhibitor in Kuwait.
Kanyike FB; Abdul-Salam SA; Prakash B; Sharhan A; Wahib N; Youssef AH
Haemophilia; 1999 Jul; 5(4):273-5. PubMed ID: 10469183
[TBL] [Abstract][Full Text] [Related]
13. Home treatment of mild to moderate bleeding episodes using recombinant factor VIIa (Novoseven) in haemophiliacs with inhibitors.
Key NS; Aledort LM; Beardsley D; Cooper HA; Davignon G; Ewenstein BM; Gilchrist GS; Gill JC; Glader B; Hoots WK; Kisker CT; Lusher JM; Rosenfield CG; Shapiro AD; Smith H; Taft E
Thromb Haemost; 1998 Dec; 80(6):912-8. PubMed ID: 9869160
[TBL] [Abstract][Full Text] [Related]
14. Safety, pharmacokinetics and efficacy of factor VIIa formulated with PEGylated liposomes in haemophilia A patients with inhibitors to factor VIII--an open label, exploratory, cross-over, phase I/II study.
Spira J; Plyushch O; Zozulya N; Yatuv R; Dayan I; Bleicher A; Robinson M; Baru M
Haemophilia; 2010 Nov; 16(6):910-8. PubMed ID: 20491957
[TBL] [Abstract][Full Text] [Related]
15. Differential response to bypassing agents complicates treatment in patients with haemophilia and inhibitors.
Berntorp E
Haemophilia; 2009 Jan; 15(1):3-10. PubMed ID: 19016901
[TBL] [Abstract][Full Text] [Related]
16. FEIBA versus NovoSeven in hemophilia patients with inhibitors.
Franchini M; Coppola A; Tagliaferri A; Lippi G
Semin Thromb Hemost; 2013 Oct; 39(7):772-8. PubMed ID: 24014071
[TBL] [Abstract][Full Text] [Related]
17. Recombinant Factor VIIa concentrate versus plasma derived concentrates for the treatment of acute bleeding episodes in people with haemophilia and inhibitors.
Iorio A; Matino D; D'Amico R; Makris M
Cochrane Database Syst Rev; 2010 Aug; (8):CD004449. PubMed ID: 20687076
[TBL] [Abstract][Full Text] [Related]
18. Recombinant VIIa concentrate in the management of bleeding following prothrombin complex concentrate-related myocardial infarction in patients with haemophilia and inhibitors.
Hough RE; Hampton KK; Preston FE; Channer KS; West J; Makris M
Br J Haematol; 2000 Dec; 111(3):974-9. PubMed ID: 11122162
[TBL] [Abstract][Full Text] [Related]
19. The use of agents that by-pass factor VIII inhibitors in patients with haemophilia.
Roberts HR
Vox Sang; 1999; 77 Suppl 1():38-41. PubMed ID: 10529686
[No Abstract] [Full Text] [Related]
20. Clinical efficacy of prothrombin complex concentrates and recombinant factor VIIa in the treatment of bleeding episodes in patients with factor VII and IX inhibitors.
Barthels M
Thromb Res; 1999 Aug; 95(4 Suppl 1):S31-8. PubMed ID: 10499907
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
